Mirdametinib Gains FDA Nod for NF1-PN

Mirdametinib Gains FDA Nod for NF1-PN

The FDA approved mirdametinib (Gomekli) for adults and children 2 years and older with neurofibromatosis type 1 (NF1) and symptomatic plexiform neurofibromas (PN) that are not resectable surgically.